Twelve-Month Follow-Up of Dexamethasone Implants for Macular Edema from Various Diseases in Vitrectomized and Nonvitrectomized Eyes
المؤلفون المشاركون
Berrocal, Maria H.
Wu, Lihteh
Badaró, Emmerson
Novais, Eduardo
Maia, Mauricio
Garcia, Jose Mauricio Botto de Barros
Louzada, Ricardo Noguera
Avila, Marcos
Filho, Paulo Augusto de Arruda Mello
Dias, João Rafael de Oliveira
Andrade, Gabriel C. de
Arevalo, J. Fernando
Farah, Michel Eid
Maia, André
المصدر
العدد
المجلد 2016، العدد 2016 (31 ديسمبر/كانون الأول 2016)، ص ص. 1-6، 6ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2016-09-18
دولة النشر
مصر
عدد الصفحات
6
التخصصات الرئيسية
الملخص EN
Purpose.
To evaluate the best-corrected visual acuity (BCVA), central retinal thickness (CRT), and the number of dexamethasone implants needed to treat cystoid macular edema (CME) from various etiologies over 12 months in vitrectomized and nonvitrectomized eyes.
Methods.
This multicenter retrospective cohort study included 112 patients with CME secondary to retinal diseases treated pro re nata (PRN) with a 0.7 mg intravitreal dexamethasone implant for 12 months.
The BCVA, CRT, adverse events, safety data, and number of implants were recorded.
Results.
Vitrectomized and nonvitrectomized eyes received means of three implants and one implant, respectively, over 12 months ( P < 0.001 ).
The mean BCVA of all patients improved from 0.13 at baseline to 0.33 ( P < 0.001 ) 12 months after one ( P = 0.001 ), two ( P = 0.041 ), and three ( P < 0.001 ) implants but not four implants ( P = 0.068 ).
The mean baseline CRT decreased significantly ( P < 0.001 ) from 463 to 254 microns after 12 months with one ( P < 0.001 ), two ( P = 0.002 ), and three ( P = 0.001 ) implants but not with four implants ( P = 0.114 ).
The anatomic and functional outcomes were not significantly different between vitrectomized and nonvitrectomized eyes.
Increased IOP was the most common adverse event (23.2%).
Conclusions.
Dexamethasone implant administered PRN improved VA and decreased CRT in CME, with possible long-term clinically relevant benefits for treating CME from various etiologies.
Vitrectomized eyes needed more implants compared with nonvitrectomized eyes.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Novais, Eduardo& Maia, Mauricio& Filho, Paulo Augusto de Arruda Mello& Dias, João Rafael de Oliveira& Garcia, Jose Mauricio Botto de Barros& Andrade, Gabriel C. de…[et al.]. 2016. Twelve-Month Follow-Up of Dexamethasone Implants for Macular Edema from Various Diseases in Vitrectomized and Nonvitrectomized Eyes. Journal of Ophthalmology،Vol. 2016, no. 2016, pp.1-6.
https://search.emarefa.net/detail/BIM-1110072
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Novais, Eduardo…[et al.]. Twelve-Month Follow-Up of Dexamethasone Implants for Macular Edema from Various Diseases in Vitrectomized and Nonvitrectomized Eyes. Journal of Ophthalmology No. 2016 (2016), pp.1-6.
https://search.emarefa.net/detail/BIM-1110072
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Novais, Eduardo& Maia, Mauricio& Filho, Paulo Augusto de Arruda Mello& Dias, João Rafael de Oliveira& Garcia, Jose Mauricio Botto de Barros& Andrade, Gabriel C. de…[et al.]. Twelve-Month Follow-Up of Dexamethasone Implants for Macular Edema from Various Diseases in Vitrectomized and Nonvitrectomized Eyes. Journal of Ophthalmology. 2016. Vol. 2016, no. 2016, pp.1-6.
https://search.emarefa.net/detail/BIM-1110072
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1110072
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر